The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 01, 2010
Filed:
Jan. 06, 2006
Hiroshi Kase, Tokyo, JP;
Akihisa Mori, Chiba, JP;
Yutaka Waki, Princeton, NJ (US);
Yutaka Ohsawa, London, GB;
Akira Karasawa, Shizuoka, JP;
Yoshihisa Kuwana, Shizuoka, JP;
Hiroshi Kase, Tokyo, JP;
Akihisa Mori, Chiba, JP;
Yutaka Waki, Princeton, NJ (US);
Yutaka Ohsawa, London, GB;
Akira Karasawa, Shizuoka, JP;
Yoshihisa Kuwana, Shizuoka, JP;
Kyowa Hakko Kirin Co., Ltd., Tokyo, JP;
Abstract
The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine Areceptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine Areceptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine Areceptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine Areceptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.